Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Issue 5 (9th July 2020)

• Record Type: Journal Article
• Authors: Verma, Shefali Setia; Bergmeijer, Thomas O.; Gong, Li; Reny, Jean‐Luc; Lewis, Joshua P.; Mitchell, Braxton D.; Alexopoulos, Dimitrios; Aradi, Daniel; Altman, Russ B.; Bliden, Kevin; Bradford, Yuki; Campo, Gianluca; Chang, Kiyuk; Cleator, John H.; Déry, Jean‐Pierre; Dridi, Nadia P.; Fernandez‐Cadenas, Israel; Fontana, Pierre; Gawaz, Meinrad; Geisler, Tobias; Gensini, Gian Franco; Giusti, Betti; Gurbel, Paul A.; Hochholzer, Willibald; Holmvang, Lene; Kim, Eun‐Young; Kim, Ho‐Sook; Marcucci, Rossella; Montaner, Joan; Backman, Joshua D.; Pakyz, Ruth E.; Roden, Dan M.; Schaeffeler, Elke; Schwab, Matthias; Shin, Jae Gook; Siller‐Matula, Jolanta M.; ten Berg, Jurriën M.; Trenk, Dietmar; Valgimigli, Marco; Wallace, John; Wen, Ming‐Shien; Kubo, Michiaki; Lee, Ming Ta Michael; Whaley, Ryan; Winter, Stefan; Klein, Teri E.; Shuldiner, Alan R.; Ritchie, Marylyn D.;
• Is Part Of: Clinical pharmacology & therapeutics. Volume 108:Issue 5(2020)
• Page Start: 1067
• Page End: 1077
• Publication Date: 2020-07-09
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1911
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2, 750 European ancestry individuals, using adenosine diphosphate‐induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 ( P value = 1.67e−33). After correction for CYP2C19*2 no other single‐nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e−09, 4.53e−08, and 2.60e−10, respectively). CYP2C19*2 is the strongest genetic determinant of on‐clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.